Journal article
Salvage Therapy with Sofosbuvir/Velpatasvir/Voxilaprevir in DAA-experienced Patients: Results from a Prospective Canadian Registry
Abstract
BACKGROUND: Despite the current highly effective therapies with direct-acting antiviral agents (DAAs), some patients with chronic hepatitis C virus (HCV) infection still do not achieve sustained virological response (SVR) and require retreatment. Sofosbuvir/velpatasvir/voxilaprevir (SVV) is recommended as the first-line retreatment option for most patients. The aim of this study was to evaluate the efficacy of SVV as salvage therapy after at …
Authors
Onofrio FQ; Cooper C; Borgia SM; Vachon M-L; Ramji A; Lilly LB; Wong A; Booth J; Sattar I; Morales H
Journal
Clinical Infectious Diseases, Vol. 72, No. 11, pp. e799–e805
Publisher
Oxford University Press (OUP)
Publication Date
June 1, 2021
DOI
10.1093/cid/ciaa1510
ISSN
1058-4838
Associated Experts
Fields of Research (FoR)
Sustainable Development Goals (SDG)
Medical Subject Headings (MeSH)
Aminoisobutyric AcidsAntiviral AgentsCanadaCarbamatesCyclopropanesDrug Therapy, CombinationFemaleGenotypeHepacivirusHepatitis C, ChronicHeterocyclic Compounds, 4 or More RingsHumansLactams, MacrocyclicLeucineMaleMiddle AgedProlineProspective StudiesQuinoxalinesRegistriesSalvage TherapySofosbuvirSulfonamides